Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.